An association between insulin resistance (a key feature of Met‐S) and urinary albumin excretion (a key indicator of CKD) is reported in numerous studies (Alqallaf et al., 2022), including registry data and acute challenge‐based protocols (Ahlqvist et al., 2018; Tsuda et al., 2018), suggesting that interventions that address fundamental features of Met‐S could have a knock‐on benefit regarding the progression of CKD. The gene discussed is ALB; the disease is chronic kidney disease.